Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shriya Pandey

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Cancer Letters|January 8, 2025
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor modelUjjwol Khatri, Mohamed A Gouda, Shriya Pandey, et al.
Journal of Medicinal Chemistry|December 26, 2024
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the ProteinYafeng Wang, Xueqing Hu, Shriya Pandey, et al.
RSC Medicinal Chemistry|June 11, 2025
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacyUjjwol Khatri, Neetu Dayal, Kofi B Owusu, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Cancer Letters|January 8, 2025
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor modelUjjwol Khatri, Mohamed A Gouda, Shriya Pandey, et al.
Journal of Medicinal Chemistry|December 26, 2024
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the ProteinYafeng Wang, Xueqing Hu, Shriya Pandey, et al.
RSC Medicinal Chemistry|June 11, 2025
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacyUjjwol Khatri, Neetu Dayal, Kofi B Owusu, et al.
Pageof 1